Blow for Bristol-Myers after Opdivo/Yervoy flunks Phase III test

27 November 2018
2019_biotech_test_vial_discovery_big

Shares in New York-based drugmaker Bristol-Myers Squibb (NYSE: BMY) are faring poorly in pre-market trading, after the firm announced a Phase III trial flop for its combination Opdivo (nivolumab) plus Yervoy (ipilimumab) therapy.

The CheckMate-451 study did not meet its primary endpoint of overall survival (OS), testing the combo as a maintenance therapy for certain patients with extensive-stage small cell lung cancer (SCLC).

SCLC accounts for about 10% to 15% of all lung cancers and less than 5% of patients with extensive-stage SCLC survive two years. The five-year survival rate is 1% to 2%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology